Investigational Drug Details
| Drug ID: | D122 |
| Drug Name: | Nitric Oxide |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB00435 |
| DrugBank Description: | Nitric oxide or Nitrogen monoxide is a chemical compound with chemical formula NO. This gas is an important signaling molecule in the body of mammals including humans and is an extremely important intermediate in the chemical industry. It is also a toxic air pollutant produced by automobile engines and power plants. Nitric oxide (NO) should not be confused with nitrous oxide (N2O), a general anaesthetic, or with nitrogen dioxide (NO2) which is another poisonous air pollutant. The nitric oxide molecule is a free radical, which is relevant to understanding its high reactivity. It reacts with the ozone in air to form nitrogen dioxide, signalled by the appearance of the reddish-brown color. |
| PubChem ID: | 145068 |
| CasNo: | 10102-43-9 |
| Repositioning for NAFLD: | Yes |
| SMILES: | [N]=O |
| Structure: |
|
| InChiKey: | MWUXSHHQAYIFBG-UHFFFAOYSA-N |
| Molecular Weight: | 30.0061 |
| DrugBank Targets: | Guanylate cyclase soluble subunit alpha-2; Metallothionein-1A; Indoleamine 2,3-dioxygenase 1; Nitric oxide synthase, endothelial |
| DrugBank MoA: | Nitric oxide is a compound produced by many cells of the body. It relaxes vascular smooth muscle by binding to the heme moiety of cytosolic guanylate cyclase, activating guanylate cyclase and increasing intracellular levels of cyclic guanosine 3',5'-monophosphate, which then leads to vasodilation. When inhaled, nitric oxide produces pulmonary vasodilation. |
| DrugBank Pharmacology: | Persistent pulmonary hypertension of the newborn (PPHN) occurs as a primary developmental defect or as a condition secondary to other diseases such as meconium aspiration syndrome (MAS), pneumonia, sepsis, hyaline membrane disease, congenital diaphragmatic hernia (CDH), and pulmonary hypoplasia. In these states, pulmonary vascular resistance (PVR) is high, which results in hypoxemia secondary to right-to-left shunting of blood through the patent ductus arteriosus and foramen ovale. In neonates with PPHN, Nitric oxide improves oxygenation (as indicated by significant increases in PaO2). Nitric oxide appears to increase the partial pressure of arterial oxygen (PaO2) by dilating pulmonary vessels in better entilated areas of the lung, redistributing pulmonary blood flow away from lung regions with low ventilation/perfusion (V/Q) ratios toward regions with normal ratios. |
| DrugBank Indication: | For the treatment of term and near-term (>34 weeks) neonates with hypoxic respiratory failure |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0025 | NCT05196347 | PHASE3 | COMPLETED | NO | 2022-05-27 | 2025-03-13 | Details |
| L0040 | NCT00701714 | PHASE3 | TERMINATED | YES | 2007-09 | 2018-02-05 | Details |
| L0146 | NCT05515367 | PHASE4 | RECRUITING | NO | 2023-04-20 | 2025-01-22 | Details |
| L0272 | NCT03223883 | PHASE2 | COMPLETED | YES | 2018-06-01 | 2024-10-08 | Details |
| L0379 | NCT00483275 | PHASE4 | WITHDRAWN | NO | 2007-06 | 2011-07-21 | Details |
| L0420 | NCT00641589 | PHASE1 | COMPLETED | NO | 2006-01 | 2011-05-18 | Details |
| L0438 | NCT05196035 | PHASE3 | RECRUITING | NO | 2022-03-28 | 2025-04-13 | Details |
| L0553 | NCT01820832 | PHASE4 | UNKNOWN | NO | 2013-03 | 2013-03-29 | Details |
| L0838 | NCT02915601 | COMPLETED | YES | 2017-01-15 | 2023-07-25 | Details | |
| L1289 | NCT00534144 | PHASE1 | COMPLETED | NO | 2007-09 | 2011-09-23 | Details |
| L1396 | NCT01115543 | PHASE4 | COMPLETED | NO | 2008-08 | 2010-05-04 | Details |
| L1504 | NCT02487706 | PHASE4 | COMPLETED | NO | 2015-06 | 2015-10-01 | Details |
| L1648 | NCT01167309 | PHASE1 | COMPLETED | NO | 2010-06 | 2025-02-24 | Details |
| L1718 | NCT00077597 | PHASE3 | COMPLETED | NO | 2004-02 | 2016-11-02 | Details |
| L2317 | NCT01059825 | PHASE2 | COMPLETED | YES | 2010-02-24 | 2018-09-13 | Details |
| L2353 | NCT03380325 | COMPLETED | NO | 2016-05-11 | 2019-07-18 | Details | |
| L2651 | NCT00951392 | COMPLETED | NO | 2009-05 | 2019-05-28 | Details | |
| L2859 | NCT05443568 | ENROLLING_BY_INVITATION | NO | 2023-03-09 | 2023-12-26 | Details | |
| L3260 | NCT04824586 | PHASE4 | COMPLETED | NO | 2019-06-01 | 2021-04-01 | Details |
| L3671 | NCT00131846 | PHASE4 | COMPLETED | NO | 2004-04 | 2024-06-14 | Details |
| L3732 | NCT05791201 | PHASE1|PHASE2 | RECRUITING | NO | 2023-05-16 | 2024-12-06 | Details |
| L3895 | NCT01525238 | PHASE1 | COMPLETED | YES | 2012-07-01 | 2017-05-30 | Details |
| L4044 | NCT02273258 | PHASE1 | COMPLETED | NO | 2013-03 | 2014-10-23 | Details |
| L4248 | NCT06293417 | RECRUITING | NO | 2024-03-01 | 2024-08-27 | Details | |
| L4259 | NCT00543517 | PHASE3 | TERMINATED | NO | 2003-02 | 2015-02-10 | Details |
| L5160 | NCT00350779 | PHASE3 | COMPLETED | YES | 2006-06-12 | 2017-05-12 | Details |
| L5227 | NCT04838743 | COMPLETED | NO | 2021-04-23 | 2024-01-26 | Details | |
| L5285 | NCT03668470 | PHASE2 | COMPLETED | NO | 2019-01-31 | 2021-07-08 | Details |
| L5486 | NCT01619059 | PHASE3 | COMPLETED | YES | 2012-06 | 2016-04-22 | Details |
| L5728 | NCT03313752 | PHASE3 | UNKNOWN | NO | 2017-12-01 | 2021-03-03 | Details |
| L6015 | NCT01336023 | PHASE3 | COMPLETED | YES | 2011-05-23 | 2018-02-19 | Details |
| L6168 | NCT03426085 | PHASE2 | UNKNOWN | NO | 2016-05 | 2019-02-11 | Details |
| L6265 | NCT06647888 | RECRUITING | NO | 2024-12-03 | 2025-01-23 | Details | |
| L6329 | NCT00254254 | PHASE2 | COMPLETED | NO | 2006-02 | 2015-02-23 | Details |
| L6457 | NCT03940183 | PHASE3 | COMPLETED | NO | 2019-07-08 | 2021-01-12 | Details |
| L6492 | NCT01904383 | COMPLETED | YES | 2013-07-01 | 2019-10-02 | Details | |
| L6550 | NCT01253278 | PHASE1 | COMPLETED | NO | 2010-03 | 2011-06-10 | Details |
| L6762 | NCT00953498 | PHASE4 | COMPLETED | NO | 2007-10 | 2013-09-02 | Details |
| L7037 | NCT06021145 | PHASE4 | RECRUITING | NO | 2024-04-02 | 2024-08-09 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name | |
|---|---|---|---|---|---|---|---|
| T03 | Angiotensin-converting enzyme | ACE | INHIBITOR | Target is a single protein chain | P12821 | ACE_HUMAN | Details |
| T06 | Sulfonylurea receptor 1 | ABCC8 | Target is a single protein chain | Q09428 | ABCC8_HUMAN | Details | |
| T47 | Sialin | SLC17A5 | Target is a single protein chain | Q9NRA2 | SLC17A5_HUMAN | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00015 | 10902787 | J Clin Endocrinol Metab | Alterations in nitric oxide/cyclic-GMP pathway in nondiabetic siblings of patients with type 2 diabetes. | Details |
| A00198 | 39746795 | Ren Fail | Dapagliflozin improves diabetic kidney disease by inhibiting ferroptosis through β-hydroxybutyrate production. | Details |
| A00200 | 39804512 | Langenbecks Arch Surg | A hypocaloric protein-rich diet before metabolic surgery improves liver function in patients with obesity and diabetes : A secondary analysis of a randomized clinical trial. | Details |